cows' milk protein allergy and enteropathy
Metabolic · 2017–2023
3decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids Treatment of cows' milk anaphylaxis, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein, soy protein and… | Mar 2023 | Recommended | none received |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids, medium chain triglycerides, 2'-fucosyllactose and lacto-N-neotetraose Treatment of cows' milk protein enteropathy, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein, soy… | Nov 2022 | Recommended with restriction | input received |
| amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids Dietary management of cows' milk protein enteropathy, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein,… | Jul 2017 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.